A Phase 1 interventional study of Vedolizumab in Allogeneic Hematopoietic Stem Cell Transplantation, sponsored by Takeda. Completed at 5 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-08-26.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the initial tolerability, safety and recommended phase 2 dose of vedolizumab intravenous (IV) administered for GvHD prophylaxis along with standard GvHD prophylaxis therapy (in participants undergoing allogeneic hematopoietic stem cell transplantation [allo-HSCT]).
The drug being tested in this study is called Vedolizumab. Vedolizumab (also called MLN0002) is approved for the treatment of adult participants with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) who achieved an inadequate response, had a loss of response, or were intolerant to conventional and/or biologic treatments. This study will look at the tolerability and pharmacokinetics of Vedolizumab in participants undergoing allo-HSCT when added to standard GvHD prophylaxis (tacrolimus plus short-term methotrexate) for the prevention of acute GvHD (major complication in allo-HSCT).
The study will enroll approximately 36 participants. Participants will be assigned to different dose-escalating cohorts in order to find out the recommended phase 2 dose (RP2D) of the study:
All participants have to receive 1 injection of Vedolizumab on Day -1 before allo-HSCT and on Days 13 and 42 after allo-HSCT. If none of the participants receiving vedolizumab at 75 mg experience dose-limiting toxicities (DLTs), dose escalation will continue to 300 mg on Day -1 before allo-HSCT and on Days +13 and +42 after allo-HSCT. If the first 3 participants at 300 mg tolerate the treatment without experiencing DLTs, then the decision on whether to increase the vedolizumab IV dose in the next cohort will be guided by the PK results.
Cohorts will be escalated in same manner until the identification of RP2D. The cohort at that dose level may be expanded to include approximately 18 additional participants undergoing myeloablative conditioning or reduced-intensity conditioning (RIC) and receiving either related or unrelated allo-HSCT for the treatment of hematologic malignancies or myeloproliferative neoplasms. This group of participants will allow the further assessment of the tolerability and clinical activity of vedolizumab.
This multi-center trial will be conducted in the United States. The overall time to participate in this study will be approximately 2 years. Following the treatment period, participants who remain in remission will be followed for development of acute and chronic GvHD and safety during clinic visits at 4, 5, 6, 9, and 12 months after allo-HSCT or until death or withdrawal of consent or termination of the study by the sponsor. Participants who complete the study will attend a 12-month follow-up visit. Patients who have been discontinued from treatment will attend an end of treatment visit 30 to 40 days after the last dose of study drug using all study procedures outlined for the 12-month follow-up visit.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Is undergoing matched or single-antigen mismatched unrelated-donor myeloablative transplant for the treatment of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML); Is less than or equal to (\<=) 60 years of age.
For the cohort after RP2D
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
Drug: Vedolizumab
Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
Drug: Vedolizumab
Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.
Drug: Vedolizumab
Vedolizumab Injection.
Number of Participants With Dose-Limiting Toxicities (DLTs)
DLTs was based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and was defined as any of following events: Grade 3 or higher toxicity assessed by the investigator as related to vedolizumab treatment; Grade 4 or higher regimen-related organ toxicities; and failure to engraft by Day +28. Engraftment was defined as absolute neutrophils count (ANC) greater than (\>) 500 per cubic millimeter (/mm\^3) for 3 consecutive days or \>2000/mm\^3 for 1 day.
Time frame: Baseline up to Day 28
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Up to 18 weeks after last dose of study drug
Mean Serum Concentrations of Vedolizumab That Helped the Likelihood of Alpha4Beta7 Target Saturation on Day 100 Following Allo-HSCT
Time frame: Day 100
Time to Neutrophil Engraftment
Time to neutrophil engraftment (recovery of ANC) was defined by an ANC \>500/mm\^3 for 3 consecutive days or \>2000/mm\^3 for 1 day. Time to neutrophil engraftment was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval.
Time frame: Baseline up to Day 100
Percentage of Participants With Overall Grade 2 to 4 Acute Graft-Versus-Host Disease (GvHD)
GvHD grading scale was based on the modified Glucksberg criteria. The grades are defined as: Grade 1 (skin stage 1 or 2 only); Grade 2 (skin stage 3 or liver stage 1 or lower or gastrointestinal \[GI\] stage 1 or upper GI involvement); Grade 3 (skin stage 0 to 3 plus liver stage 2 to 4 or lower GI stage 2 to 3); Grade 4 (skin stage 4 or lower GI stage 4).
Time frame: Baseline up to Day 100
Percentage of Participants With Maximum Severity of Acute GvHD Based on Modified Glucksberg Criteria
Maximum severity was assessed using GvHD grading scale based on the modified Glucksberg criteria. The grades are defined as: Grade 1 (skin stage 1 or 2 only); Grade 2 (skin stage 3 or liver stage 1 or lower or GI stage 1 or upper GI involvement); Grade 3 (skin stage 0 to 3 plus liver stage 2 to 4 or lower GI stage 2 to 3); Grade 4 (skin stage 4 or lower GI stage 4).
Time frame: Baseline up to Day 100
Percentage of Participants With Maximum Severity of Acute GvHD Based on Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Modified International Bone Marrow Transplant Registry Database (IBMTR) Index
Maximum severity of acute GvHD was assessed by using BMT CTN modified IBMTR index. The severity index are defined as: Grade A (skin stage 1: extent of rash less than \[\<\] 25%); Grade B (skin stage 2: extent of rash 25 to 50% or liver stage 1 to 2: total bilirubin 34 to 102 micromole per liter \[mcmol/L\] or intestinal tract stage 1 to 2: volume of diarrhea 550 to 1500 milliliter per day \[mL/day\]); Grade C (skin stage 3: extent of rash greater than (\>) 50% or liver stage 3: total bilirubin 103 to 255 mcmol/L or intestinal tract stage 3: volume of diarrhea \>1500 mL/day); Grade D (skin stage 4: extent of rash bullae or liver stage 4: total bilirubin \>255 or intestinal tract stage 4: volume of diarrhea severe pain and ileus).
Time frame: Baseline up to Day 100
Ctrough: Serum Concentration Before Dosing for Vedolizumab
Time frame: Days 13 and 42 pre-dose
Participants took part in the study at 5 investigative sites in the United States from 15 June 2016 to 10 July 2018.
| Milestone | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| Started | 3 | 21 |
| Completed | 2 | 16 |
| Not completed | 1 | 5 |
| Withdrew: Other | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 |
DLTs was based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and was defined as any of following events: Grade 3 or higher toxicity assessed by the investigator as related to vedolizumab treatment; Grade 4 or higher regimen-related organ toxicities; and failure to engraft by Day +28. Engraftment was defined as absolute neutrophils count (ANC) greater than (\>) 500 per cubic millimeter (/mm\^3) for 3 consecutive days or \>2000/mm\^3 for 1 day.
| Participants | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) | 0 | 0 |
| Participants | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| TEAEs | 3 | 21 |
| SAEs | 2 | 11 |
| microgram per milliliter (mcg/mL) | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| Mean Serum Concentrations of Vedolizumab That Helped the Likelihood of Alpha4Beta7 Target Saturation on Day 100 Following Allo-HSCT | 7.34 ± 3.762 | 18.36 ± 11.043 |
Time to neutrophil engraftment (recovery of ANC) was defined by an ANC \>500/mm\^3 for 3 consecutive days or \>2000/mm\^3 for 1 day. Time to neutrophil engraftment was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval.
| days | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| Time to Neutrophil Engraftment | 22 (15 to 22) | 14 (13 to 17) |
GvHD grading scale was based on the modified Glucksberg criteria. The grades are defined as: Grade 1 (skin stage 1 or 2 only); Grade 2 (skin stage 3 or liver stage 1 or lower or gastrointestinal \[GI\] stage 1 or upper GI involvement); Grade 3 (skin stage 0 to 3 plus liver stage 2 to 4 or lower GI stage 2 to 3); Grade 4 (skin stage 4 or lower GI stage 4).
| percentage of participants | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With Overall Grade 2 to 4 Acute Graft-Versus-Host Disease (GvHD) | 0 (0 to 70.8) | 19.0 (5.4 to 41.9) |
Maximum severity was assessed using GvHD grading scale based on the modified Glucksberg criteria. The grades are defined as: Grade 1 (skin stage 1 or 2 only); Grade 2 (skin stage 3 or liver stage 1 or lower or GI stage 1 or upper GI involvement); Grade 3 (skin stage 0 to 3 plus liver stage 2 to 4 or lower GI stage 2 to 3); Grade 4 (skin stage 4 or lower GI stage 4).
| percentage of participants | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| Grade 1 | 66.7 (17.5 to 95.0) | 28.6 (11.3 to 55.6) |
| Grade 2 | 0 (NA to NA) | 14.3 (3.8 to 41.1) |
| Grade 3 | 0 (NA to NA) | 4.8 (0.6 to 29.7) |
| Grade 4 | 0 (NA to NA) | 0 (NA to NA) |
Maximum severity of acute GvHD was assessed by using BMT CTN modified IBMTR index. The severity index are defined as: Grade A (skin stage 1: extent of rash less than \[\<\] 25%); Grade B (skin stage 2: extent of rash 25 to 50% or liver stage 1 to 2: total bilirubin 34 to 102 micromole per liter \[mcmol/L\] or intestinal tract stage 1 to 2: volume of diarrhea 550 to 1500 milliliter per day \[mL/day\]); Grade C (skin stage 3: extent of rash greater than (\>) 50% or liver stage 3: total bilirubin 103 to 255 mcmol/L or intestinal tract stage 3: volume of diarrhea \>1500 mL/day); Grade D (skin stage 4: extent of rash bullae or liver stage 4: total bilirubin \>255 or intestinal tract stage 4: volume of diarrhea severe pain and ileus).
| percentage of participants | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| Grade A | 0 (NA to NA) | 19.0 (6.1 to 46.2) |
| Grade B | 66.7 (17.5 to 95.0) | 14.3 (3.8 to 41.1) |
| Grade C | 0 (NA to NA) | 14.3 (3.8 to 41.1) |
| Grade D | 0 (NA to NA) | 0 (NA to NA) |
| mcg/mL | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| Day 13 | 5.87 ± 3.00 | 21.34 ± 6.05 |
| Day 42 | 8.17 ± 5.20 | 29.05 ± 13.04 |
Collected over TEAEs are adverse events that started after the first dose of study drug and no more than Week 18 after the last dose of study drug. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Vedolizumab 75 mg | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Cohort 2: Vedolizumab 300 mg | 2/21 (9.5%) | 11/21 (52.4%) | 21/21 (100%) |
| Event | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| InfluenzaInfections and infestations | 1/3 | 0/21 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 2/21 |
| NauseaGastrointestinal disorders | 1/3 | 2/21 |
| Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/21 |
| Failure to thriveMetabolism and nutrition disorders | 0/3 | 2/21 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 2/21 |
| HypotensionVascular disorders | 0/3 | 2/21 |
| Acute kidney injuryRenal and urinary disorders | 0/3 | 2/21 |
| PyrexiaGeneral disorders | 0/3 | 2/21 |
| BronchitisInfections and infestations | 0/3 | 1/21 |
| Event | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg |
|---|---|---|
| StomatitisGastrointestinal disorders | 3/3 | 10/21 |
| FatigueGeneral disorders | 3/3 | 12/21 |
| Alanine aminotransferase increasedInvestigations | 3/3 | 4/21 |
| HypomagnesaemiaMetabolism and nutrition disorders | 3/3 | 17/21 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 15/21 |
| Platelet count decreasedInvestigations | 2/3 | 15/21 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 13/21 |
| VomitingGastrointestinal disorders | 2/3 | 6/21 |
| PyrexiaGeneral disorders | 2/3 | 11/21 |
| White blood cell count decreasedInvestigations | 2/3 | 7/21 |
The population of participants evaluable for vedolizumab safety was defined as all participants who received any amount of vedolizumab intravenously.
| Age, Continuous(years) | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 30.0 ± 17.44 | 52.7 ± 16.90 | 49.9 ± 18.27 |
| Sex: Female, Male(Participants) | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Female | 2 | 5 | 7 |
| Male | 1 | 16 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 3 | 18 | 21 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 3 | 19 | 22 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| United States | 3 | 21 | 24 |
| Weight(kilogram (kg)) | Cohort 1: Vedolizumab 75 mg | Cohort 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 92.93 ± 25.662 | 89.96 ± 25.836 | 90.33 ± 25.272 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Jun 2016 to primary completion in Jul 2018, 24 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab